Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone224-667-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.58 billion
Profitability
Miscellaneous
Employees103,000
Next Earnings Date4/17/2019 (Confirmed)
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Thursday, February 21st. Stockholders of record on Monday, April 15th will be paid a dividend of $0.32 per share on Wednesday, May 15th. This represents a $1.28 annualized dividend and a dividend yield of 1.64%. The ex-dividend date of this dividend is Friday, April 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Wednesday, January, 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.81. The healthcare product maker had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.55%. The company's revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 EPS. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
How can I listen to Abbott Laboratories' earnings call?
Abbott Laboratories will be holding an earnings conference call on Wednesday, April 17th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY19 earnings guidance on Wednesday, January, 23rd. The company provided earnings per share (EPS) guidance of $3.15-3.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.20. Abbott Laboratories also updated its FY 2019 guidance to $3.15-3.25 EPS.
What price target have analysts set for ABT?
18 brokerages have issued 12-month target prices for Abbott Laboratories' shares. Their forecasts range from $68.00 to $90.00. On average, they anticipate Abbott Laboratories' stock price to reach $79.6938 in the next twelve months. This suggests a possible upside of 1.9% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
What are Wall Street analysts saying about Abbott Laboratories stock?
Here are some recent quotes from research analysts about Abbott Laboratories stock:
- 1. According to Zacks Investment Research, "Abbott's emerging market performance has been promising. We are optimistic about the strong and consistent performance by the company’s EPD and Medical Devices segments organically. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip improves further following the FDA approval of its upgraded version. This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Vascular arm in the United States continues to dent growth. Increasing currency headwinds to some extent dented Abbott’s international performance in the last-reported quarter. Overall, Abbott has been outperforming the industry over the past six months." (3/19/2019)
- 2. BTIG Research analysts commented, "Q4 was a mixed bag with reported revenue and margin falling short of consensus’ expectations, mostly due to f/x. Organic revenue growth was 6.4%, sequentially slower on the surface. However, ABT overcame its toughest comp in Q4 but smoothed for comps, revenue growth continued its upward trajectory. Importantly, ABT’s initial FY19 revenue outlook of 6.5-7.5% came in slightly ahead of our forecast. We think there is still a good chance 1.0/2.0 can nudge this range higher. Management noted that hitting the FY19 revenue range is not predicated on either a meaningful ramp in MitraClip or Libre 2.0 rollout in the U.S. The company also suggested that tweaks to underperforming areas like Neuromod should easily drive performance to the higher end of the range. Overall, we see little risk to the ABT story but see the valuation of 22x NTM EPS as appropriate." (1/24/2019)
Has Abbott Laboratories been receiving favorable news coverage?
Headlines about ABT stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abbott Laboratories earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave media headlines about the healthcare product maker a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
What other stocks do shareholders of Abbott Laboratories own?
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 64)
- Mr. Robert B. Ford, Pres & COO (Age 45)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 40)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.89%), Massachusetts Financial Services Co. MA (1.92%), Oregon Public Employees Retirement Fund (1.71%), Northern Trust Corp (1.51%), Bank of New York Mellon Corp (1.39%) and FMR LLC (1.35%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, Joseph J Manning, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which institutional investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Prudential Financial Inc., Bank of New York Mellon Corp, American Century Companies Inc., Canada Pension Plan Investment Board, Diamond Hill Capital Management Inc., Lord Abbett & CO. LLC and Flossbach Von Storch AG. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Miles D White, Roger Bird and Sharon J Bracken. View Insider Buying and Selling for Abbott Laboratories.
Which institutional investors are buying Abbott Laboratories stock?
ABT stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, FMR LLC, BlackRock Inc., Sustainable Growth Advisers LP, Geode Capital Management LLC, Epoch Investment Partners Inc. and GQG Partners LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks and John G Stratton. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $78.23.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $137.41 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
